Fortis

Algeta ASA (OSL:ALGETA) Results highlight the potential of Alpharadin to treat bone metastases in major cancer indications

Algeta ASA (OSL:ALGETA) Oslo, Norway, 16 December 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces its financial calendar 2009.

Algeta ASA (OSL:ALGETA) Appointment enhances Algeta's commercial capabilities and aims to accelerate further development of Alpharadin in advanced prostate cancer

Algeta ASA (OSL:ALGETA) Oslo, Norway, 13 November 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announces that Dr. Thomas Ramdahl, President and Chief Executive Officer, will be presenting at the Lazard Capital Markets 5th Annual Healthcare Conference to be held at the St. Regis Hotel, 2 East 55th Street, New York City, from November 18 - 19, 2008.

Algeta ASA (OSL:ALGETA) Alpharadin - Phase III ALSYMPCA study in hormone-refractory prostate cancer patients now enrolling

Algeta ASA (OSL:ALGETA) Oslo, Norway, 3 November 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, will announce its third quarter 2008 results on Wednesday, 5 November 2008. A presentation to investors, analysts and the press will take place in Oslo at 08:15 CET and an international conference call will take place at 14:30 CET (details below). Algeta's President and Chief Executive Officer, Dr. Thomas Ramdahl and Chief Financial Officer, Øystein soug will participate.

Algeta ASA (OSL:ALGETA) Oslo, Norway, 19 September 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announced today that the third quarter results will be presented on 5 November, not on November 12 as previously announced.

Algeta ASA (OSL:ALGETA) Oslo, Norway, 16 September 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announced today that the extraordinary general meeting in Algeta ASA was held on 15 September, and all items on the agenda were resolved.

Algeta ASA (OSL:ALGETA) Please find notice of an Extra Ordinary General Meeting in Algeta ASA enclosed.

Algeta ASA (OSL:ALGETA) Results further support the clinical profile of this novel anti-cancer agent under development to improve the survival of patients with hormone refractory prostate cancer (HRPC)